Get the Stockscreener App
0.3633
9.04%
-0.0361
After Hours:
.36
-0.0033
-0.91%
Immunoprecise Antibodies Ltd stock is traded at $0.3633, with a volume of 645.30K.
It is down -9.04% in the last 24 hours and down -19.80% over the past month.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
See More
Previous Close:
$0.3994
Open:
$0.3795
24h Volume:
645.30K
Relative Volume:
0.10
Market Cap:
$16.63M
Revenue:
$16.77M
Net Income/Loss:
$-11.87M
P/E Ratio:
-0.7661
EPS:
-0.4742
Net Cash Flow:
$-5.90M
1W Performance:
-7.79%
1M Performance:
-19.80%
6M Performance:
-43.23%
1Y Performance:
-77.85%
1-Day Range:
$0.3521
$0.381
1-Week Range:
$0.35
$0.4097
52-Week Range:
$0.30
$1.714
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Name
Immunoprecise Antibodies Ltd
Sector
Industry
Phone
-
Address
-
Compare IPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
0.3633 | 16.63M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Oct-25-21 | Initiated | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Stock (IPA) Latest News
ImmunoPrecise Q3 Earnings Postponed: Auditors Request Extra Time for Goodwill Review - StockTitan
ImmunoPrecise Antibodies Reschedules Q3 Financial Results Release - TipRanks
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 | FinancialContent - Financial Content
Immunoprecise Antibodies Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Short Interest Update - Defense World
ImmunoPrecise Antibodies (IPA) to Release Earnings on Thursday - Defense World
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery - ACCESS Newswire
ImmunoPrecise Antibodies to Announce Q3 Fiscal 2025 Results - TipRanks
AI Antibody Pioneer ImmunoPrecise Sets March 13 Earnings CallWhat's Next for This Biotech Innovator? - StockTitan
ImmunoPrecise Antibodies Ltd. (IPA) Expands AI Leadership with Dr. Kamil Isaev Appointment - Insider Monkey
IPA and Ribopro form mRNA antibody discovery collaboration - Yahoo Finance
ImmunoPrecise Antibodies appoints Joseph Scheffler interim CFO - MSN
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy - 01Net
ImmunoPrecise & RIBOPRO Partner for AI-Powered Antibody Discovery - Contract Pharma
ImmunoPrecise Antibodies and RIBOPRO Partner to Revolutionize Antibody Discovery - TipRanks
ImmunoPrecise Antibodies annonce un remaniement de son équipe de direction - The Hastings Tribune
ImmunoPrecise Antibodies Announces Key Leadership Changes - Business Wire
AI Pioneer Joins ImmunoPrecise Board: Can New Leadership Accelerate Biotech Innovation? - StockTitan
ImmunoPrecise Antibodies Transfers to Nasdaq Capital Market, Gains Extension - TipRanks
Immunoprecise Antibodies Announces Transfer To Nasdaq Capital Market And Extension Of Bid Price Compliance Period - Marketscreener.com
ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period - Business Wire
ImmunoPrecise Antibodies Ltd (IPA) Shares Up Despite Recent Market Volatility - The News Heater
Check Out ImmunoPrecise Antibodies Ltd (IPA)’s Trade Data Rather Than the Analysts’ Views - SETE News
ImmunoPrecise Antibodies Ltd (IPA) presents a great opportunity, but the stock is slightly overvalued - US Post News
ImmunoPrecise Antibodies Boosts Financial Position Through Successful Capital Initiatives - TipRanks
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Shares Down 3.9% – Here’s Why - Defense World
ImmunoPrecise Antibodies Ltd. (IPA) Unveils AI-Developed GLP-1 Therapies for Type 2 Diabetes and Obesity, Pioneering New Frontiers in Biotech Innovation - Insider Monkey
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture - The Globe and Mail
ImmunoPrecise Antibodies Strengthens Financial Position with Strategic Capital Initiatives - TipRanks
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology - ACCESS Newswire
Benchmark maintains Buy on Immunoprecise stock, target at $3.00 - MSN
Benchmark maintains Buy on Immunoprecise stock, target at $3.00 By Investing.com - Investing.com Canada
Immunoprecise uses AI to develop new class of GLP-1 therapies - BioWorld Online
ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI - Yahoo Finance
Stock Traders Buy High Volume of ImmunoPrecise Antibodies Call Options (NASDAQ:IPA) - Defense World
What's Going On With ImmunoPrecise Antibodies Stock Wednesday? - Benzinga
S&P 500 Growth (IGX) QuotePress Release - The Globe and Mail
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Global Mining Index (TXGM) QuotePress Release - The Globe and Mail
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therap - GuruFocus.com
ImmunoPrecise Antibodies Leverages AI for Next-Gen Diabetes Treatment - TipRanks
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment - Business Wire
ImmunoPrecise Antibodies Ltd. (IPA) Launches AI-Powered Drug Discovery Pipeline, Revolutionizing Therapeutic Development with LENSai™ Platform - Insider Monkey
10 Trending AI Stocks on Latest News and Ratings - Insider Monkey
ImmunoPrecise launches AI-driven drug discovery pipeline - Investing.com India
ImmunoPrecise launches AI-driven drug discovery pipeline By Investing.com - Investing.com Canada
ImmunoPrecise Antibodies Launches AI-Powered Drug Discovery Platform - TipRanks
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Business Wire
Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely - Simply Wall St
Immunoprecise Antibodies Ltd Stock (IPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):